Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach